Navigation Links
Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
Date:1/7/2008

SAN JOSE, Calif., Jan. 7 /PRNewswire/ -- Tacere Therapeutics, Inc., an RNA interference (RNAi)-based therapeutics developer, announced today that it has entered into a collaboration and license agreement with Pfizer Inc. to develop and commercialize its Hepatitis C virus (HCV) compound, TT-033. The collaboration will focus on completing all necessary studies for submission of an investigational new drug application (IND), as well as clinical development and commercialization of TT-033.

"We are very pleased about forming a collaborative relationship with Pfizer, and are excited about being first in the industry to partner an expressed RNAi drug," said Sara M. Hall, Chief Executive Officer of Tacere. "We have made excellent progress in the research and preclinical development of TT-033, and are very happy to be joined by Pfizer at an important time in the program's development. Pfizer recognizes the potential of this first-in- class approach to provide a novel treatment option for HCV patients and we look forward to working with the team at Pfizer to advance TT-033."

Mike Catelani, Chairman, President and CFO of Tacere, stated, "We look forward to combining Pfizer's and Tacere's complementary capabilities to take TT-033 into the clinic. We are pleased that Pfizer has chosen to work with us in developing this potential single administration RNAi drug to aid in the fight against the global healthcare crisis of HCV."

Under the terms of the agreement, Tacere and Pfizer will form a joint steering committee to oversee preclinical research and development efforts for TT-033. Pfizer will fund all aspects of the collaboration, including the preclinical development work and will have exclusive worldwide rights, excluding all Asian countries, to commercialize products that result from the collaboration.

During the initial phase of the collaboration, Pfizer will provide Tacere with funding in order to complete the necessary IND-enabling studies
'/>"/>

SOURCE Tacere Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013   Accuray Incorporated ... publication of study results involving hundreds of prostate ... System, the most widely used form of prostate ... 304 patients for a median of 5 years, ... that 97 percent of patients with low-risk and ...
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
(Date:5/21/2013)... 21, 2013 Abaxis, Inc. (NasdaqGS: ABAX), a ... today that Martin Mulroy , chief ... Dental & Veterinary Conference on Wednesday, May 29, 2013 ... at Le Parker Meridien Hotel in New ... Abaxis develops, manufactures, markets and sells portable blood ...
Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2
... May 7 Patients treated with the ... at two years, according to interim results from ... a late-breaking clinical trial at the Society for ... Sessions. The prospective, single-arm study is ongoing to ...
... Inc. (NYSE: HRC ) today announced its fiscal 2010 third quarter dividend of ... 6, 2010 , and is payable on June 30, 2010 , to shareholders of record ... , , ABOUT ... Hill-Rom is a leading worldwide manufacturer and ...
Cached Medicine Technology:Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 3
(Date:5/21/2013)... The Special Olympics Missouri State Summer Games ... the state to Columbia. This state-level event takes place May ... and Columbia College, and at Hickman High School and Town ... kick off at 7:30 p.m. Friday, May 30 with the ... theme, the Parade of Athletes, the culmination of the statewide ...
(Date:5/21/2013)... Venice Beach, Calif. (PRWEB) May 21, 2013 ... to treating a dual diagnosis of Borderline Personality Disorder ... therapy that is proving to be successful for the ... Saturday, June 1, Alina Gorgorian, Ph.D., clinical director ... treatment in Los Angeles, will provide attendees of ...
(Date:5/21/2013)... autism showed significant improvement after six months of simple ... scents, spoons and sponges, according to UC Irvine neurobiologists. ... enrichment led to notable gains in male subjects between ... in Behavioral Neuroscience . , Study co-authors Cynthia ... one of two groups, balanced for age and autism ...
(Date:5/21/2013)... 2013 STAR (Sensory Therapies And ... with sensory challenges and the Sensory Processing Disorder ... and advocacy of Sensory Processing Disorder present Stumbling Blocks ... Improve Quality of Life, a two-hour lecture presented by ... , Learn a method that can aid in ...
(Date:5/21/2013)... Chicago, IL (PRWEB) May 21, 2013 ... business process integration solutions, today announced it is the ... by analyst firm 451 Research. The report, “Adeptia Bets ... in-depth review of the company, its strategy, products, pricing, ... are in need of a framework for integration and ...
Breaking Medicine News(10 mins):Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 2Health News:Special Olympics Missouri Athletes Ready to Show Off Skills in Columbia 3Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 2Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 3Health News:Enrichment therapy effective among children with autism, UCI study finds 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 2Health News:STAR Center and SPD Foundation Present a Lecture on Teens and Adults with Sensory Processing Disorder 3Health News:Adeptia Featured in Recent 451 Research Impact Report 2
... common condition, researchers say , TUESDAY, March 30 (HealthDay News) ... deep vein thrombosis, it is most likely to occur on ... researchers have found. , Dr. Wee-Shian Chan of Women,s ... review, said in a news release that the clots most ...
... Osmosis Day ... business with more than 200,000 of the unique healing bath treatments delivered in a Japanese ... Freestone, CA (PRWEB) ... chicken coop, Osmosis, a day spa in Sonoma County California , has delivered more ...
... from arthritis and osteoporosis to broken bones that won,t ... a key molecular player to keep stem cells in ... makes treatment with the cells in the future more ... the cells, known as mesenchymal (pronounced meh-ZINK-a-mill) stem cells, ...
... and the American Society of Hematology (ASH) have selected ... EHA-ASH Research Exchange Award, which serves to strengthen ties ... Ingmar Bruns is a resident physician and research scientist ... at the University of Dsseldorf in Germany. After graduating ...
... ... Serve Spanish-Speaking Patients , ... (PRWEB) March 30, 2010 -- The HealthLinkRx Institute has announced news dates ... sessions of the Institute’s “Therapy in Spanish” class will be offered in Austin, TX ...
... , TUESDAY, March 30 (HealthDay News) -- Researchers have ... be linked to autism disorders. , "To our knowledge, ... of association between these important genes in brain connections ... of the Wellcome Trust Center for Human Genetics at ...
Cached Medicine News:Health News:California Day Spa - Osmosis Celebrates 25th Anniversary With Over 200,000 Cedar Enzyme Baths Given 2Health News:California Day Spa - Osmosis Celebrates 25th Anniversary With Over 200,000 Cedar Enzyme Baths Given 3Health News:Promoting healing by keeping skeletal stem cells 'young' 2Health News:Promoting healing by keeping skeletal stem cells 'young' 3Health News:European hematologist receives award to conduct research in US 2Health News:HealthLinkRx Announces Classes in Spanish for Occupational and Physical Therapists 2
... Olympus has pioneered the ... neurosurgical imaging system, an innovative ... be more efficient and less ... consists of the OME-7000 surgical ...
The Leica MS1 F/MC1 F is designed to mount on the ceiling with a high degree of mobility. Its unique and patented suspension concept assures a superior stability and a perfect and steady microscope i...
... SheerVision surgical magnifying loupes are ... quality optics which provide the healthcare ... and greater depth of field. Each ... in a fully lined wooden box ...
... Advantage delivers higher magnification for advanced surgical ... image, even at the highest magnification. 3.5x, ... and precise color rendition is ideal for ... anti-reflective coating produce a superior image. The ...
Medicine Products: